Variantyx

Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology. Our unique, comprehensive testing platform uses whole genome sequencing to identify all major genetic changes from a single sample. The results empower patients and providers with information that can rapidly end the challenging diagnostic search, optimize treatment, and improve quality of life. We are a diverse, multinational company that embodies professionalism, transparency, tenacity, and respect. See more with us: www.variantyx.com/.

Nona Biosciences

Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs by diversified partnership strategies including co-discovery, platform and antibody discovery, and platform license. The values of the antibody discovery platforms and flexible partnership models have been well validated by more than 50 industry and academic partners within over 200 projects.

Pioneering Medicines

Pioneering Medicines, Flagship Pioneering’s in house drug discovery and development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship’s innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship’s multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts and then works jointly with Flagship’s companies to form integrated teams that advance medicines through robust discovery and early clinical development. Pioneering Medicines also partners with external collaborators across biopharma throughout the R&D process, applying its unique approach to the R&D priorities of partners through highly co-creative relationships. The team leads Flagship’s Innovation Supply Chain Partnerships with Novo Nordisk and Pfizer to speed innovation in drug development and bring novel therapies to patients, as well as a partnership with the Cystic Fibrosis Foundation to develop therapeutics that address the unmet needs of people living with cystic fibrosis.

Partner Therapeutics

WE'RE ALL IN FOR FIGHT AGAINST CANCER Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes. THE PATIENT IS NUMBER ONE We believe that being a cancer company begins and ends with the patient. We strive to support patient needs throughout their treatment journey to help them make the treatment choices that are right for them and their loved ones. FIGHTING CANCER IS TEAM SPORT We believe that cancer is a complex, dynamic disease that requires a multi-faceted, multi-disciplinary approach to tackle. We believe in teamwork at each stage of a therapy’s development, and seek to build teams of experts, both internally and externally, that cover the breadth and depth of the complex problem that is cancer. We work with leading companies and investigators to ensure that our products are tested in the best settings, and in combination with highest potential regimens to maximize benefit to patients and to advance the understanding of cancer treatment. We seek to engage all members of the cancer treatment team as well as thought-leading physicians and patient advocacy organizations to ensure that clear, complete and balanced information about our products is proactively communicated and readily available. We work to support the extraordinary dedication of the medical teams that represent the front lines in the war on cancer. OUTCOMES ARE OUR YARDSTICK We believe that innovation is not enough. In the challenging world of today’s healthcare climate, we strive to develop and assess our products based on the real-world impact they have in improving the quality and duration of our patients’ lives. We measure our success in the birthdays, anniversaries and other important life moments that our patients are able to enjoy.

Manus

Manus is the world’s leading bioalternatives scale-up platform. We work with companies across industries and value chains to accelerate the transition to bioalternatives – better performing and more sustainable versions of complex molecules traditionally sourced from plants, animals, or fossil fuels. Our platform is proven to work across scales, bridging the Valley of Death between lab and manufacturing more efficiently and more reliably to deliver the benefits of synthetic biology, today.